Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

Was the risk any different for their RSV drug?

respiratory syncytial virus did not meet the primary endpoint in a Phase 2b clinical trial. The therapy did not reduce symptoms when compared to placebo;

Yes, the risk was very different as the ENTA drug EDP-938 has a novel MOA. In stark contrast, the MOA of Covid protease inhibitors is well defined and there is already a successful drug. By the way, ENTA is suing PFE for patent infringement over Paxlovid.

The recent EDP-938 failed trial was in otherwise healthy adults that had RSV. EDP-938 educed RVS levels but symptom relief was improved but didn't reach significance. The next trials are in very young people and in high risk patents. For Covid reference, Paxloivid's success has been in olde high risk patients, not as a prophylaxis.